Provided by Tiger Trade Technology Pte. Ltd.

Tiziana Life Sciences PLC

1.24
-0.0100-0.80%
Post-market: 1.240.00000.00%18:33 EDT
Volume:179.86K
Turnover:227.48K
Market Cap:157.48M
PE:-10.85
High:1.35
Open:1.26
Low:1.23
Close:1.25
52wk High:2.60
52wk Low:0.7301
Shares:127.00M
Float Shares:68.78M
Volume Ratio:0.94
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1143
EPS(LYR):-0.1112
ROE:-232.31%
ROA:-83.78%
PB:17.12
PE(LYR):-11.15

Loading ...

Tiziana Life Sciences Ltd. Director and 10% Owner Gabriele M. Cerrone Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

BUZZ-Tiziana Life Sciences rises as nasal MS drug shows promise in early study

Reuters
·
Feb 25

Tiziana reports biomarker data linking nasal foralumab to reduced CSF inflammation and microglial PET signal in na-SPMS patients with PIRA

Reuters
·
Feb 25

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates Csf Inflammation, Upregulates Neuroprotective Pathways, and Correlates With Reduced Microglial Activation on Pet Scans in Na-Spms Patients With Pira

THOMSON REUTERS
·
Feb 25

Tiziana Life Sciences announces publication of intranasal foralumab results

TIPRANKS
·
Jan 21

Tiziana Life Sciences Publishes Positive Clinical Results for Intranasal Foralumab in Progressive MS

Reuters
·
Jan 21

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

THOMSON REUTERS
·
Jan 21

Tiziana Life Sciences Launches Registered Direct Offering With Attached Warrants

Reuters
·
Jan 16

Press Release: Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Dow Jones
·
Jan 16

Tiziana Life Sciences to Present Intranasal Foralumab at Neuroscience Innovation Forum

Reuters
·
Jan 09

Tiziana Life Sciences Executive Chairman Gabriele Cerrone Acquires 97,687 Shares

Reuters
·
Dec 20, 2025

Tiziana Life Sciences Publishes AGM Presentation

Reuters
·
Dec 18, 2025

Tiziana Life Sciences Rings Nasdaq Closing Bell

Reuters
·
Dec 17, 2025

Tiziana Life Sciences Doses First Patient in Phase 2 Trial of Intranasal Foralumab for Early Alzheimer’s Disease

Reuters
·
Dec 17, 2025

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

THOMSON REUTERS
·
Dec 17, 2025

Tiziana Life Sciences CEO Increases Stake With Share Purchase

MT Newswires Live
·
Dec 16, 2025

Tiziana Life Sciences CEO Purchases 163,400 Shares in Open Market

Reuters
·
Dec 16, 2025

Tiziana Life Sciences Falls on Withdrawn Public Offering

Dow Jones
·
Dec 15, 2025

Tiziana Life Sciences Withdraws Proposed Public Offering

MT Newswires Live
·
Dec 15, 2025

BRIEF-Tiziana Life Sciences Announces Withdrawal Of Proposed Public Offering

Reuters
·
Dec 15, 2025